Drug intelligence / Profile preview

M3

Development stage: Unknown
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

M3 is a component of an investigational HIV-1 vaccine regimen, C1C62-M3M4, designed to evaluate safety and immunogenicity in persons with HIV-1 suppressed on antiretroviral therapy. It is administered as an intramuscular injection as part of a sequential vaccination schedule. The vaccine aims to improve the immune system's response to help the body clear HIV from cells.

Targets

HIV (HIV-1 enzymes)

Beyond the preview

Go deeper on M3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M3.

Explore the full profile